Adenocarcinoma of prostate
Item
histologically (the study of tissue under the microscope) or cytologically (the study of cells) confirmed adenocarcinoma (a malignant epithelial tumor with a glandular organization) of the prostate
boolean
C0007112 (UMLS CUI [1])
Neoplasm Metastasis X-Ray Computed Tomography
Item
radiologically (gamma and computed topography [ct] scans) documented metastatic disease
boolean
C0027627 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
Chemotherapy Docetaxel Based Hormone refractory prostate cancer metastatic
Item
at least 6 weeks of treatment with 1 prior docetaxel-based chemotherapy for metastatic hormone refractory prostate cancer (hrpc)
boolean
C0392920 (UMLS CUI [1,1])
C0246415 (UMLS CUI [1,2])
C1705938 (UMLS CUI [1,3])
C1328504 (UMLS CUI [1,4])
C1522484 (UMLS CUI [1,5])
Disease Progression | Therapeutic procedure Docetaxel Based Discontinued | Serum Prostate Specific Antigen Increased | Disease Progression Diagnostic radiologic examination | Disease Progression Radioisotope scan of bone | Bone lesion New Quantity | wound | Sore skin | Exanthema | furuncle
Item
disease progression, during or within 6 months of stopping of prior docetaxel-based therapy, based on one of the following: serum prostate specific antigen (psa) progression, defined as a rise in at least 2 consecutive serum psa values, each obtained at least 1 week apart or radiologic disease progression: if disease progression is shown by bone scan only, then disease progression is defined by the appearance of 2 or more new bone lesions (abnormal area of tissue, such as a wound, sore, rash, or boil)
boolean
C0242656 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0246415 (UMLS CUI [2,2])
C1705938 (UMLS CUI [2,3])
C1444662 (UMLS CUI [2,4])
C1883014 (UMLS CUI [3])
C0242656 (UMLS CUI [4,1])
C0043299 (UMLS CUI [4,2])
C0242656 (UMLS CUI [5,1])
C0203668 (UMLS CUI [5,2])
C0238792 (UMLS CUI [6,1])
C0205314 (UMLS CUI [6,2])
C1265611 (UMLS CUI [6,3])
C0043250 (UMLS CUI [7])
C1442877 (UMLS CUI [8])
C0015230 (UMLS CUI [9])
C0242301 (UMLS CUI [10])
Orchiectomy | Testosterone amount caused by Medical Castration | Testosterone amount caused by Chemical male castration
Item
orchiectomy (surgery to remove one or both testicles) or testosterone less than 50 nanogram per decilliter (ng/dl) by means of pharmacological/chemical castration
boolean
C0029189 (UMLS CUI [1])
C0039601 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0015127 (UMLS CUI [2,3])
C1513054 (UMLS CUI [2,4])
C0039601 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0015127 (UMLS CUI [3,3])
C0455189 (UMLS CUI [3,4])
Brain Neoplasm Evidence
Item
no evidence of a brain tumor
boolean
C0006118 (UMLS CUI [1,1])
C3887511 (UMLS CUI [1,2])
Chemotherapy Regimen Quantity Metastatic Prostate Carcinoma
Item
no more than 1 line of chemotherapy for metastatic prostate cancer
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0936223 (UMLS CUI [1,3])
Mitoxantrone
Item
no prior mitoxantrone treatment
boolean
C0026259 (UMLS CUI [1])
Malignant Neoplasm | Prostate carcinoma | Superficial carcinoma of urinary bladder Treated | Basal cell carcinoma Treated | Squamous cell carcinoma of skin Treated | Malignant Neoplasm Disease Free of
Item
prior malignancy (other than prostate cancer) except adequately treated superficial bladder cancer, basal cell or squamous cell carcinoma (type of cancer) of the skin, or other cancer for which the subject has been disease-free for atleast 3 years
boolean
C0006826 (UMLS CUI [1])
C0600139 (UMLS CUI [2])
C1336527 (UMLS CUI [3,1])
C1522326 (UMLS CUI [3,2])
C0007117 (UMLS CUI [4,1])
C1522326 (UMLS CUI [4,2])
C0553723 (UMLS CUI [5,1])
C1522326 (UMLS CUI [5,2])
C0006826 (UMLS CUI [6,1])
C0012634 (UMLS CUI [6,2])
C0332296 (UMLS CUI [6,3])
HIV Seropositivity | Hepatitis B | Hepatitis C
Item
no human immunodeficiency virus (hiv) (a life-threatening infection that you can get from an infected person's blood or from having sex with an infected person) seropositivity or hepatitis (inflammation of the liver) b or c infection
boolean
C0019699 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])